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Abstract 
Periodontal diseases are among the most common diseases affecting humans. Dental biofilm is a 
contributor to the etiology of most periodontal diseases. It is also widely accepted that immunological 
and inflammatory responses to biofilm components are manifested by signs and symptoms of 
periodontal disease. The outcome of such interaction is modulated by risk factors (modifiers), either 
inherent (genetic) or acquired (environmental), significantly affecting the initiation and progression of 
different periodontal disease phenotypes. While definitive genetic determinants responsible for either 
susceptibility or resistance to periodontal disease have yet to be identified, many factors affecting the 
pathogenesis have been described, including smoking, diabetes, obesity, medications, and nutrition. 
Currently, periodontal diseases are classified based upon clinical disease traits using radiographs and 
clinical examination. Advances in genomics, molecular biology, and personalized medicine may result in 
new guidelines for unambiguous disease definition and diagnosis in the future. Recent studies have 
implied relationships between periodontal diseases and systemic conditions. Answering critical 
questions regarding host-parasite interactions in periodontal diseases may provide new insight in the 
pathogenesis of other biomedical disorders. Therapeutic efforts have focused on the microbial nature of 
the infection, as active treatment centers on biofilm disruption by non-surgical mechanical debridement 
with antimicrobial and sometimes anti-inflammatory adjuncts. The surgical treatment aims at gaining 
access to periodontal lesions and correcting unfavorable gingival/osseous contours to achieve a 
periodontal architecture that will provide for more effective oral hygiene and periodontal maintenance. 
In addition, advances in tissue engineering have provided innovative means to regenerate/repair 
periodontal defects, based upon principles of guided tissue regeneration and utilization of growth 
factors/biologic mediators. To maintain periodontal stability, these treatments need to be 
supplemented with long-term maintenance (supportive periodontal therapy) programs. 
Periodontology has been defined as ‘the scientific study of the periodontium in health and disease’ (6). 
The periodontium includes the gingiva, alveolar bone, periodontal ligament and root cementum, i.e. the 
tissues that support the teeth. The anatomy, histology and physiology of the normal periodontium have 
been described in great detail elsewhere.347 They will not be covered in this context. 
People exhibiting periodontal abnormalities, for example impairments of tissue integrity or function, are 
said to have periodontal diseases. These comprise a variety of phenotypes; defined by clinical signs and 
symptoms, they constitute the periodontal syndrome.44, 397, 404 The most frequently observed phenotype 
is inflammation of the gingiva (gingivitis) induced by dental plaque (biofilm), and includes changes in 
tissue color, volume, temperature, crevicular exudate and bleeding upon gentle provocation with a 
probe.251 The clinical signs of biofilm-associated gingivitis are reversible when adequate oral hygiene is 
implemented and maintained.232 Less prevalent than gingivitis, but still observed in many persons, are 
the clinical signs of biofilm-associated periodontitis. They include periodontal pockets, attachment loss, 
bleeding upon probing, and radiographic bone loss.117 Therapeutic efforts are directed towards 
elimination of the suspected underlying infection, typically leading to resolution of the signs of 
inflammation, tissue repair, and restoration of function and esthetics. The results of periodontal therapy 
may be stable over a long time period, but signs of disease may return unpredictably in terms of 
location, frequency and severity. 
Many other phenotypes, frequently disease forms with severe signs and symptoms, have been 
described and classified.145, 201 They are much less prevalent than typical biofilm-associated gingivitis or 
periodontitis. Some of the rare forms are related to systemic conditions; others are components of 
genetic syndromes. Diagnostic criteria frequently used to characterize the various phenotypes of 
periodontal syndrome are listed in Table 1. 
Table 1.  Diagnostic criteria used for periodontal diseases. A diagnosis can be made if two or more 
diagnostic signs are present. The initial diagnosis is further characterized using two or more modifiers 
Diagnostic signs and symptoms 
 Gingival color (or texture, volume or contour) 
 Gingival necrosis 
 Gingival enlargement 
 Gingival recession 
 Bleeding on provocation 
 Bleeding on probing 
 Pockets 
 Attachment loss 
 Bone loss 
 Tooth mobility 
 Lateral migration 
 Pain 
Modifiers 
 Age of onset (early or adult) 
 Progression (chronic or rapid) 
 Response to treatment (stable or recurrent) 
 Severity (mild, moderate or severe) 
 Extent (localized or generalized) 
The objective of this overview of principles of periodontology is presentation of current and established 
concepts. Aspects of the history, classification, etiology, pathogenesis, epidemiology and treatment 
modalities of the most common periodontal diseases are discussed. 
History 
Early Observations 
Periodontal diseases, unlike caries, are not a by-product of modern civilization. Manifesting themselves 
as ante mortem loss of alveolar bone, signs indicative of periodontal pathology were discovered in 
human specimens attributed to the Middle Pleistocene stage. For instance, indications of alveolar bone 
resorption were found in the 640- to 735,000-year-old Mauer mandible (Homo heidelbergensis) in 
Germany, and in a 169- to 191,000-year-old mandible that was unearthed at the Bau de l’Aubésier, 
Vaucluse, France.91, 224 Such findings support the theory that periodontal diseases have plagued humans 
and their phylogenetic ancestors for a very long time. 
Chinese physicians were probably first to describe signs of periodontal diseases. Diagnoses and 
treatments were presented in the earliest known textbook of Chinese medicine, Nei Ching, attributed to 
Huang Di (approximately 2700–2600 BC).357 The ancient Egyptian Ebers Papyrus was written 
approximately 1000 years later (approximately 1550 BC). It is one of the oldest fully preserved 
medical documents, and contains several passages on remedies to cure conditions such as loose teeth 
and swollen gums (‘flesh’).139 In Ancient India, Sushruta (approximately 6th century BC) illustrated a 
large number of surgical instruments, and explained 300 surgical procedures in the treatise Samhita. 
Sushruta taught a holistic approach to medical therapy. In pursuit of his philosophy, he described four 
periodontal conditions, offering probably the first classification of periodontal diseases.357 
In 1563, the Italian Renaissance anatomist and physician Bartolomeo Eustachi (1514–1574) completed 
‘Libellus de Dentibus’, the first book dedicated exclusively to the description of teeth.127 He was the first 
to describe the periodontal ligament, as well as the deciduous and permanent dentitions. Eustachi’s 
profound understanding of head anatomy and his amazing eye for the detail led him to link increased 
tooth mobility at an advanced age with widening of the space between the root and the alveolar bone. 
Similarly remarkable, he prescribed the removal of calculus and granulation tissue using scalers and 
curettes, respectively, to encourage re-attachment of periodontal tissues to loose teeth.358 
From scurvy of the gum to Riggs’ disease 
Almost two centuries after Eustachi, the French surgeon-dentist Pierre Fauchard (1678–1761) published 
‘Le Chirurgien Dentiste’, a two-volume book dedicated to the practice of dentistry. Fauchard’s 
comprehensive work profoundly influenced the practice of dentistry. He pointed out that any dental 
disease can be allocated to one of only three classes, namely: (1) diseases with external cause, (2) 
(hidden) diseases that attack those tooth parts embedded in the periodontium, and (3) (symptomatic) 
diseases caused by the teeth.113 Critical of the theories accepted by most physicians of his time, 
Fauchard postulated a humoral etiology of periodontal disease that is modulated by local factors, e.g. 
calculus. To prevent ‘gum disease’, he recommended cleaning the teeth, massaging the gingiva with an 
astringent liquid, and washing the mouth with wine and water. Because of the spongy appearance of the 
gingiva that had similarity to gingiva he observed in patients with scurvy, Fauchard called the phenotype 
‘scurvy of the gums’. 
Fifty years later, the Scottish surgeon and scientist John Hunter (1728–1793) published ‘A Practical 
Treatise on the Diseases of the Teeth intended as a supplement to the Natural History of those Parts’, 
his second and less popular book on teeth and tooth-related structures. Hunter postulated that gradual 
loss of alveolar bone, associated pocket formation and gingival recession would inevitably result in tooth 
loss. He considered the process to be disease when it occurred early in life, but the result of natural 
aging in the elderly. Among gingival diseases, Hunter distinguished between cases that resembled 
Fauchard’s ‘scurvy of the gums’ and cases of overgrown fibrotic tissue.176 
Achievements in microbiology, a novel scientific discipline in the 19th century, changed the way 
periodontal diseases were viewed. Two German physicians, Robert Ficinus (1809–1852) and Adolph 
Witzel (1847–1906), deserve credit for associating bacteria with periodontal tooth loss.63 In Europe, the 
term ‘alveolar pyorrhea’ was coined to describe any form of periodontal disorder unrelated to the aging 
process. According to Witzel, in patients exhibiting alveolar pyorrhea, the gingiva forms a pocket that 
allows bacteria to infect and destroy the underlying periosteum and ultimately alveolar bone. In the 
USA, John M. Riggs (1810–1885), also known as the father of periodontics, treated diseased pockets by 
painstakingly thorough calculus removal, curettage of soft tissues, and implementation of meticulous 
individual oral hygiene. He was convinced that all stages of periodontal disease, from the earliest signs 
of inflammation to tooth loss, were attributable to the same local etiology, i.e. calculus. Reportedly, 
Riggs’ rigorous procedure healed more than 90% of his patients, a huge improvement over any 
previously known treatment. His success was soon recognized. In 1869, the Connecticut Valley Dental 
Association passed a resolution acknowledging Riggs as the first person ever to treat gum inflammation 
successfully.264 Riggs’ achievement also had a lasting effect on dental terminology; in the USA, the term 
‘scurvy of the gums’ was replaced by ‘Riggs disease’. Not for long, however. At the 1877 meeting of the 
American Dental Association, the Germany-born physician Frederick H. Rehwinkel (1825–1889) 
presented a paper on ‘pyorrhea alveolaris’, and ever since has been credited for introducing the 
European term to the American dental literature.263 The term ‘pyorrhea alveolaris’ was quickly adopted 
by the dental community. It persisted deep into the 20th century, despite being rather a poor choice for 
the disease it purported to describe. 
Focal infection theory 
Willoughby D. Miller (1853–1907), whose work was very much influenced by Robert Koch, is best known 
for his groundbreaking ideas on the etiology of caries. He also postulated a role for bacteria in the 
etiology of alveolar pyorrhea,270 and concluded that, in the presence of predisposing factors, many 
bacteria found normally in the mouth can cause periodontal disease (e.g., non-specific plaque 
hypothesis). Miller advocated that such bacteria could also play a role in the etiology of many other 
diseases in humans. He coined the expression ‘focus of infection’.271 but stopped short of promoting 
eradication of infected teeth to prevent or treat systemic illnesses. This step was made by Frank Billings 
(1854–1932), a highly respected American physician and academic leader. Billings and his student and 
colleague Edward C. Rosenow (1875–1966) promoted the theory of focal infection in the USA.51, 331 Like 
Miller, Billings spent time in Europe, where the germ theory of disease, initiated by the groundbreaking 
discoveries of Koch, Lister, Pasteur and other luminaries, was heavily debated. According to Billings’ 
theory, the germ carrier harbors pleiomorphic microorganisms that may cause disease at any time. 
Dissemination of such germs from a latent localized infection to a distant organ would occur through the 
blood and lymphatic systems. The focal infection paradigm was quickly adopted by many dentists and 
physicians, especially surgeons in the USA. Its clinical implementation, which was further promoted by 
substantial improvements in asepsis, led to uncountable unwarranted tooth extractions, tonsillectomies 
and other surgical procedures.135 In 1928, Holman publicly questioned the validity of the focal infection 
theory.164 Its importance started to decline in the 1930s as evidence accumulated indicating that surgical 
removal of suspected foci has no beneficial effect on the medical status of affected patients.65, 326 It is 
tempting to speculate about apparent similarities between the focal infection theory and the so-called 
‘systemic link’. However, a closer look at the basis of the two paradigms reveals fundamental 
discrepancies, especially with regard to bacterial pleiomorphism and tissue lesion latency. 
Periodontal disease classifications 
Times of transition and consolidation 
At the dawn of the 20th century, the realization that alveolar pyorrhea can be treated led to recognition 
of ‘periodontia’ as a dental specialty. The professional organization of periodontists now known as the 
American Academy of Periodontology was established in 1914 as the American Academy of Oral 
Prophylaxis and Periodontology. In Germany, the ‘Arbeitsgemeinschaft für Paradentosen Forschung’ 
was formed in 1924 with the goal of establishing an open communication platform for academicians and 
practitioners. However, the much needed information exchange was impeded by decidedly inconsistent 
terminology. Over subsequent decades, periodontists on both sides of the Atlantic met repeatedly to 
develop countless classification systems that reflected scientific progress as well as clinical utility. As a 
result of this effort, new nomenclatures were published at arbitrary intervals by professional bodies 
such as the American Academy of Periodontology, the American Dental Association, the 
Arbeitsgemeinschaft für Paradentosen Forschung and the World Dental Federation, among others. In 
addition, classifications were also contributed by individual authors. 
One of the major biomedical accomplishments of the 20th century was the recognition that formal 
hypotheses can be tested in the clinic. Application of quantitative methods to clinical problem solving, 
albeit implemented slowly in most dental disciplines, had profound effects on the classification of 
periodontal diseases. The paucity of scientific evidence in support of periodontosis and occlusal trauma 
as classes of periodontal disease was initially acknowledged at the 1966 World Workshop in 
Periodontics,1 and formalized 11 years later at the International Conference on Biology of Periodontal 
Disease. Only two classes of periodontal disease remained – juvenile periodontitis and chronic marginal 
periodontitis417 – and these constituted the 1977 American Academy of Periodontology classification 
system. 
In the meantime, the studies on experimental gingivitis by Harald Löe and his collaborators at the Royal 
Dental College in Aarhus, Denmark, ushered in the ‘plaque era’ of periodontology. Using novel index 
systems to assess plaque and gingivitis,231, 360 they provided unequivocal experimental evidence for a 
direct relationship between the presence of dental bacterial plaque and gingivitis.232, 233, 390 In addition, 
they demonstrated the full reversibility of all clinical signs of gingival pathology when oral hygiene was 
re-established. There is no question that the nature and results of these ground-breaking studies had a 
profound effect on most aspects of clinical periodontology. 
Moreover, a destructive form of periodontal disease, most frequently observed around the central 
incisors and first molars in young people, initiated renewed interest in the disease class previously 
known as periodontosis. Baer45 and Manson & Lehner248 published initial clinical reports that were 
followed by studies of host defense mechanisms.74, 77, 406 Because it was frequently diagnosed in 
adolescent patients, the form was re-named juvenile periodontitis.At the time of the 1977 International 
Conference on Biology of Periodontal Disease, the majority opinion among dentists was that, without 
treatment, gingivitis progresses to periodontitis, at a relatively constant rate, ultimately resulting in 
tooth loss. This view was challenged when Löe et al.234 presented their results on the natural history of 
periodontal diseases. Performed in Sri Lanka in a population with no access to dental services and 
virtually no home care, the longitudinal study suggested the presence of three distinct sub-populations 
exhibiting clearly discernible patterns of disease progression: a cohort with no or minimal disease 
progression over time, a cohort with moderate disease progression, and a cohort with rapid disease 
progression. In most subjects, the presence of plaque and gingivitis did not lead to severe periodontitis 
or tooth loss. The centuries-old belief that linked alveolar bone and tooth loss to ageing was finally 
disproved. 
These and other findings were reflected in a new classification that was first suggested at the 1986 
World Workshop in Clinical Periodontics and modified at the World Workshop in Clinical Periodontics in 
1989.2 The revised system distinguished five classes of periodontal disease. In comparison to the 1986 
taxonomy, a new class was introduced for periodontal diseases linked to systemic conditions. Moreover, 
criteria for disease onset and rate of progression were considered. One of the more obvious 
shortcomings of the 1989 classification was the absence of a category for gingival diseases. Also, many 
practicing periodontists felt that the emphasis of the classification on patient age at disease onset was 
not suitable for long-term patient care. 
Finally, in 1993, the European Academy of Periodontology (now the European Federation of 
Periodontology) was founded at the 1st European Workshop on Periodontology. The European Academy 
of Periodontology adopted the American Academy of Periodontology’s 1989 classification but suggested 
that an improved system should be considered based on three major classes: early-onset periodontitis, 
adult periodontitis and necrotizing periodontitis. Each of these was further defined by secondary 
descriptors (distribution within dentition, progression rate, treatment response, relation to systemic 
disease, microbiological characteristics, etc.).32 
 
1999 International Workshop for Classification of Periodontal Diseases and 
Conditions 
The currently used classification (2010) was implemented based on recommendations by the 1999 
International Workshop for a Classification of Periodontal Diseases and Conditions (Table 2).29 In 
addition to increasing the number of disease classes from five to eight, the revision included several 
substantial deviations from preceding classifications. Briefly, gingival diseases were included as an 
independent entity (class I). Chronic periodontitis (class II) and aggressive periodontitis (class III) 
replaced adult periodontitis and early-onset periodontitis, respectively, thus eliminating the classifier 
‘age’. The refractory class was abandoned, periodontitis as manifestation of systemic diseases (class 
IV) was modified and restricted to include only genetic and hematological diseases, and necrotizing 
periodontal diseases (class V) replaced necrotizing ulcerative periodontitis. Categories for abscesses of 
the periodontium (class VI), periodontitis associated with endodontic lesions (class VII) and 
developmental or acquired deformities and conditions (class VIII) completed the new classification 
system. Although not perfect, it reflects the current scientific understanding of the nature of periodontal 
diseases, as well as the practice of periodontics. In the subsequent sections, the terminology of the 1999 
classification will be used as appropriate. 
Table 2.  1999 Classification of periodontal diseases and conditions 
I: Gingival diseases 
 A Dental plaque-induced gingival diseases 
 B Non-plaque-induced gingival lesions 
II: Chronic periodontitis 
 A Localized 
 B Generalized (>30% of sites are involved) 
III: Aggressive periodontitis 
 A Localized 
 B Generalized (>30% of sites are involved) 
IV: Periodontitis as a manifestation of systemic diseases 
 A Associated with hematological disorders 
 B Associated with genetic disorders 
 C Not otherwise specified 
V: Necrotizing periodontal diseases 
 A Necrotizing ulcerative gingivitis 
 B Necrotizing ulcerative periodontitis 
VI: Abscesses of the periodontium 
 A Gingival abscess 
 B Periodontal abscess 
 C Pericoronal abscess 
VII: Periodontitis associated with endodontic lesions 
 A Combined periodontic–endodontic lesions 
VIII: Developmental or acquired deformities and conditions 
 A Localized tooth-related factors that modify or predispose to plaque-induced 
gingival diseases/periodontitis 
 B Mucogingival deformities and conditions around teeth 
 C Mucogingival deformities and conditions on edentulous ridges 
 D Occlusal trauma 
 
Classification limitations and next steps 
Periodontal disease classification has evolved over a long time period. As such, it is the result of major 
paradigm shifts30 that collectively have defined modern periodontology. Needless to say, all 
classifications have had their shortcomings, which exposed them to considerable criticism.44, 175, 300, 323, 404 
Armitage30 probably put it best when he concluded that: ‘Any attempt to group the entire constellation 
of periodontal diseases into an orderly and widely accepted classification system is fraught with 
difficulty, and inevitably considerable controversy. No matter how carefully the classification is 
developed, and how much thought and time are invested in the process, choices need to be made 
between equally unsatisfactory alternatives’. 
The purpose of disease classification is to unambiguously link clinical phenotypes, defined by clinical 
observations and simple laboratory investigations, with diagnoses and ultimately disease-specific 
therapy (Table 3). The currently used system is a combination of broadly defined classification elements 
such as location, etiology and pathology. Some disease classes (II and III) are further refined using rule-
based criteria, e.g. slight chronic periodontitis is defined by the inclusion criterion ‘1–2 mm of clinical 
attachment loss’. Other classes (I, IV and VIII) use relationship definitions rather than operational 
definitions for allocation of cases to sub-classes, e.g. periodontitis as a ‘manifestation of’ Down 
syndrome. Technically, allocation of a clinical phenotype to a disease class is achieved using information 
collected in a standard periodontal examination. Due to the inherent simplicity of the required clinical 
procedures, classification is an easy task for specialists in periodontics. 
Table 3.  Typical general characteristics of an ideal classification system 
• The classification corresponds to the nature of the disease being classified 
• Every member of the universe of periodontal diseases (‘periodontal syndrome’) will fit in one 
and only one class/sub-class in the classification system 
• The classification is useful 
• The number of sub-classes is not excessive 
• The set of classes can be constructed using a systematic procedure 
 
However, as mentioned above, the current classification has also received challenges. Of general 
concern is that some clinical phenotypes do not meet the classification criteria of any particular disease 
class. Examples have been described in the literature,175, 300 and concern non-inflammatory destructive 
periodontal disease or atrophy. A weakness of many disease classifications is substantial overlap among 
classes. This occurs when the key properties of classes are too broadly defined. In such situations, 
clinical phenotypes cannot be allocated unequivocally, and mis-classification is possible. An example is 
the definition of aggressive periodontitis (class III) as ‘rapid attachment loss and bone destruction’. 
Here the critical identifier refers to a subjective, temporal interpretation of a cross-sectional finding 
rather than objective information that can be obtained from patient examinations and records. 
However, there is no universal agreement on threshold rates for rapid attachment loss and bone 
destruction. To mitigate the risk of mis‐classification, selected biochemical (e.g. interleukin‐1β and 
prostaglandin E2) and microbiological (e.g. Porphyromonas gingivalisand Aggregatibacter 
actinomycetemcomitans) secondary identifiers have been proposed.221 Another concern is the 
sensitivity and specificity of the methods used to collect patient information. Data on change in probing 
depth, clinical attachment and radiographic bone level are collected as the result of disease history. The 
methods used to generate such information lack the sensitivity required to detect the subtle sub-clinical 
changes that occur before tissue damage is clinically obvious. In addition, they are associated with 
substantial measurement error, which affects diagnostic specificity. 
Our understanding of the fundamental mechanisms involved in onset and progression of most diseases, 
including those affecting the periodontium, remains incomplete. The already substantial amount of 
knowledge acquired from clinical and laboratory research regarding the etiology and pathomechanisms 
responsible for periodontal diseases has not yet paid off in terms of development of potent preventive 
and therapeutic measures for the individual patient. However, this situation will change. Progress 
achieved in the post-genomic disciplines of transcriptomics, proteomics, metabolomics and systems 
biology will permit a much more accurate and precise characterization and definition of disease at the 
phenotype level. In the not so distant future, such information could be used for identification of 
phenotypic differences among patients suffering from the same disease, subsequently leading to 
individualized, patient-specific therapies.239 
Etiology 
It is accepted that dental plaque microorganisms existing in the form of biofilms are primary etiological 
agents of periodontal diseases. Biofilms are matrix-enclosed bacterial communities that adhere to each 
other and to surfaces or interfaces. Enormous advances in biology and technology have provided ever 
more sophisticated tools for the investigation of dental biofilms. Introduction of the GasPak system59 
and the anaerobic glove box27 allowed discovery of numerous fastidious anaerobic planktonic species in 
the oral cavity.274, 365 Due to this advancement in anaerobiosis, coupled with epidemiological data, it was 
possible to associate a population shift toward certain gram-negative anaerobic species in dental plaque 
biofilms with the initiation and progression of periodontal diseases. However, it was the application of 
DNA-based assays, polymerase chain reaction and confocal microscopy71, 206, 212, 217, 304, 366 that deepened 
our understanding of the formation, maturation and ecology of dental plaque biofilms. 
The epithelia lining the mouth and the exposed tooth surfaces constitute the adherence substrate for 
oral biofilms (Fig. 1). Oral bacteria are initially acquired by contact with an infected family member at 
birth or at later life stages.401 The conditions for bacteria to initiate successful colonization vary greatly 
depending on tissue type, location, and exposure to external shear forces. The gingival sulcus, and 
especially the col region, which forms the bridge between adjacent gingival papillae, offer protected 
niches that favor bacterial settling. Pioneer colonizers include oral species of the 
genera Streptococcus, Veillonella, Prevotella, Neisseria, Gemella, Actinomyces and others.302 During 
biofilm maturation, bacteria interact with each other within and between species via surface-associated 
structures (co-aggregation), leading to a unique spatial organization.229 As part of a sophisticated 
ecological system, biofilm residents communicate through exchange of genetic information and quorum 
sensing, a mechanism that allows coordination of their gene expression according to population 
density.47, 379 In addition, biofilm bacteria facilitate processing and uptake of nutrients, and protect 
themselves from other species (by producing bacteriocins), the host and harsh environments,245 
allowing them to establish stable communities.214 
 
Figure 1. Properties of bacterial biofilms. Bacterial cells in a biofilm are held together by a matrix 
composed of extracellular polysaccharides, proteins, and other compounds. Biofilm development occurs 
in response to extracellular signals, both environmental and self‐produced. Biofilms protect bacteria 
from a wide array of insults as diverse as antibiotics, predators, and the human immune system. The 
biofilm shown in the figure was grown for 3 days on a human enamel sliver worn by a healthy 
volunteer in the region of the maxillary premolars and molars. The surface to be imaged was facing 
towards the natural teeth to simulate retention areas. The biofilm was stained using fluorescent in 
situ hybridization (FISH) to show streptococci (yellow) and all bacteria (red). Reflected imaging (blue) was 
used to show the surface of the plaque and the slime matrix between the bacteria in the biofilm. The 
plaque biofilm was composed of dense clusters of streptococci interspersed with clusters formed by other 
bacteria. The scales on the x, y and z axes are in 1 μm increments. Biofilm image courtesy of Drs. 
Christiane von Ohle (Department of Conservative Dentistry, Tübingen, Germany) and Paul Stoodley 
(National Centre for Advanced Tribology Southampton, Southampton University, UK). 
Mature dental biofilms can host a large variety of bacterial genera. Molecular detection of the 
microflora in the oral cavity has led to identification of approximately 700 bacterial species or 
phylotypes.12, 212, 304 Approximately 50–60 species can be identified in a typical plaque sample when 16S 
rRNA probes are used.329 16S rRNA is a highly conserved gene sequence that permits estimation of 
evolutionary distance and relatedness of organisms.78 Species compositions of dental biofilms vary 
greatly from sample to sample and are site-specific.305 From initial colonization to formation of mature 
and potentially pathogenic supra- and subgingival communities, dental biofilms pass through several 
stages, including colonization, growth of commensal bacteria, and integration and invasion of 
pathogenic species.207 Such opportunistic pathogens co-exist with other biofilm residents until changed 
environmental conditions favor their expansion and expression of their pathogenic properties. The 
bacterial composition of mature biofilms sampled in the gingival sulcus of periodontally healthy subjects 
over an extended time period shows a high level of temporal stability. In contrast, in subjects whose 
clinical status changes from health to disease or vice versa, many bacterial species disappear or 
emerge.213, 368, 384 Likewise, periodontal diseases are considered to be opportunistic polymicrobial 
infections. Putative bacterial pathogens associated with periodontal diseases have been identified in 
subgingival biofilms. These include A. actinomycetemcomitans, P. gingivalis, Tannerella 
forsythia, Treponema denticola, Prevotella intermedia, Fusobacterium nucleatum, Eikenella 
corrodens, Campylobacter rectus, Parvimonas micra (previously Peptostreptococcus micros) 
and Streptococcus intermedius. Three species, P. gingivalis, T. forsythia and T. denticola, have been 
designated as ‘the red complex’,367 and are implicated in progression of chronic periodontitis. Numerous 
virulence factors, which can initiate and modulate pathways of the host response, were identified and 
characterized from these species.165, 386 P. gingivalis(previously Bacteroides gingivalis), a gram-negative 
black-pigmented, immotile obligate anaerobe, is a late or secondary colonizer that depends on the 
presence of other biofilm species.281 Its virulence potential is characterized by: (1) adhesion and co-
aggregation mediated by fimbriae, vesicles, several hemagglutinins and outer membrane proteins, (2) 
evasion of host responses mediated by capsule lipopolysaccharides, and immunoglobulin and 
complement proteases, and (3) tissue damage mediated by a large number of peptidases that enable 
tissue invasion and destruction, and production of toxic metabolic end-
products.281 T. forsythia (previously Bacteroides forsythus) is a fastidious, non-motile, spindle-shaped, 
obligate anaerobic gram-negative rod whose growth in biofilms depends on co-aggregation 
with P. gingivalis or F. nucleatum. It secretes proteolytic enzymes and sialidase, and can induce 
apoptosis. Furthermore, T. forsythia can adhere to and invade epithelial cells and extracellular matrix 
components via the cell surface-associated BspA protein. The invasion is enhanced in the presence 
of P. gingivalis.177 In addition, T. forsythia possesses a unique surface structure called a surface (S-) layer 
that is involved in hemagglutination and adherence/invasion of epithelial cells.335 T. denticola is a gram-
negative, aero-tolerant anaerobic spirochete. It is a late colonizer, and adheres readily to other bacteria, 
such as P. gingivalis, T. forsythia and F. nucleatum, using various adhesins. T. denticola also possesses 
numerous proteinases and peptidases. The functions of selected virulence factors identified from these 
periodontal pathogens have been validated by construction of isogenic mutants and animal studies.166 
Aggregatibacter actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans)285 is a 
putative pathogen that has been associated with aggressive (previously known as ‘juvenile’) forms of 
periodontitis.115, 363, 429 The oral cavity is its only known natural habitat. It is isolated regularly and in large 
numbers from various oral mucosal surfaces, even in toddlers and in the absence of periodontal 
pathology.218, 385 Serotype b, one of five defined serotypes, can be isolated primarily from periodontal 
pockets in subjects with localized aggressive periodontitis.428 In addition to its ability to 
colonize, A. actinomycetemcomitans can invade epithelial cells,265 secrete a leukotoxin42, 157 and induce 
apoptosis.192 A. actinomycetemcomitans shows clonality in virulence, as leukotoxin production is greatly 
increased in clone JP2.199 This clone belongs to serotype b and has a 530 bp deletion in the promoter 
region of the leukotoxin gene operon. This deletion is most likely responsible for the increased toxin 
production. Originally discovered in an 8-year-old Moroccan child with aggressive periodontitis,149 the 
clone has also been isolated from Africans with a history of aggressive periodontitis in other parts of the 
world. The restriction of infection with JP2 to individuals of West- and North-African descent implies 
great colonization stability and a vertical transmission pathway from mother to child. Moreover, this 
allowed the investigators to track JP2’s emergence on the African continent back in time for hundreds of 
years.199 While infection with JP2 is a somewhat unique finding, it sheds light on the importance of 
specific bacteria in certain forms of periodontal disease, as well as the potential value of microbiological 
screening309 for early detection in susceptible subjects. 
Pathogenesis 
The characteristic gingival and periodontal lesions are the result of biofilm-induced, orchestrated 
inflammatory responses involving the innate and adaptive arms of the immune system. Inflammation 
that remains limited to the gingiva is the outcome of a well-balanced symbiosis between biofilms and 
the host tissues, while periodontitis is the result of breakdown of this symbiosis. Moreover, it may be 
speculated that even the most common forms of periodontal diseases are merely analogous phenotypes 
of different pathogenetic pathways, initiated by biofilm products, of which only a few lead to tissue 
destruction in susceptible hosts. Much progress has been made at all levels of inquiry towards 
understanding these pathways.209, 295, 296, 298 Figure 2 shows a highly simplified model of the inflammatory 
pathway that can lead to tissue destruction, and it is explained below. 
 
 
Figure 2. Inflammatory pathways are initiated by biofilm bacteria or products, and ultimately produce a 
tissue response, i.e. gingivitis or periodontitis. The type and strength of the response are determined by 
pathogen‐associated molecular patterns (PAMPs) and the subject’s genetic make‐up, and modulated by 
the presence or absence of modifying factors, including diabetes, obesity, smoking, and others. For 
example, the PAMP lipopolysaccharide from gram‐negative bacteria (e.g. Porphyromonas 
gingivalis or Tannerella forsythia), first binds via the CD14 receptor to Toll‐like receptor 4, a pattern 
recognition receptor (PRR) that is expressed on polymorphonuclear leukocytes, as well as gingival and 
junctional epithelia. Activation of Toll‐like receptor 4 also requires the presence of protein MD2, and 
engages a set of response proteins. Subsequently, intracellular signal cascades are turned on, resulting in 
a Toll‐like receptor‐specific reaction. Transition from the innate to the adaptive response is initiated by 
Toll‐like receptor‐triggered cytokine and chemokine production, and involves activation of antigen‐
presenting cells, as well as T‐cell differentiation and regulation. 
Basically, dental plaque biofilms are in constant interaction with their underlying substrates, i.e. the 
tooth surface, junctional epithelium, gingival epithelium and pocket epithelium. They receive nutrients 
from the saliva, crevicular fluid, cell debris and food. Considering biofilms a nuisance, without any 
benefit to the host, may be a big mistake. Not only do biofilms affect the host, there is mounting 
evidence that the host’s responses similarly influence the metabolism and composition of biofilms. In a 
healthy person, host defense and biofilms co-exist in a mutually beneficial symbiotic state.167, 253 
Bacteria are released continuously from dental biofilms, and to a large extent are eliminated before they 
elicit any host response. Significant bacterial invasion is not observed in subjects with clinically healthy 
periodontal tissues. Various physiological mechanisms are in place to maintain tissue integrity; bacterial 
products are rinsed off by the continuous saliva flow, crevicular fluid flushes the gingival sulcus, and the 
high turnover of the junctional and gingival epithelia eliminates bacteria-loaded superficial cells.60, 348 
In addition to the mechanical cleansing action, highly potent first-line antimicrobial defense systems can 
sense and destroy intruders. Such systems include peptides found in the saliva (histatins, cathelicidins 
and others), epithelium, neutrophils,93 and molecules described as pattern recognition receptors 
(PRRs).73 α‐defensins are observed in the junctional epithelium, where they are associated with 
polymorphonuclear leukocytes. These cells constantly migrate towards the gingival sulcus, responding 
to a gradient of interleukin-8 that is expressed in the junctional and sulcus epithelium.395 β‐defensins are 
found in gingival and pocket epithelia, where they are constitutively expressed.211 In addition to 
exhibiting excellent antibacterial properties, defensins can activate the complement cascade, up-
regulate production of the chemokine interleukin-8 in epithelial cells, and attract immune cells.254 PRRs 
are typically found on the surface of polymorphonuclear leukocytes, macrophages, dendritic cells, 
endothelial cells, mucosal epithelium cells and lymphocytes.189 They include two functional families. 
Endocytic PRRs are located on the surface of phagocytes. They facilitate the attachment of 
microorganisms, leading to their engulfment and destruction. Signaling PRRs are located on the surface 
of a greater variety of cells. They recognize structurally highly conserved pathogen-associated molecular 
patterns (PAMPs) on microorganisms. PAMPs include lipopolysaccharide, teichoic acids, sugar 
residues, N-formyl peptides and others. Binding of PAMPs to PRRs promotes the synthesis and secretion 
of intracellular regulatory molecules such as cytokines that are crucial for initiating innate immunity and 
adaptive immunity. 
Recently, Toll-like receptors, a subgroup of the signaling family of PRRs, were identified in periodontal 
tissues.246 Interaction between a PRR and its PAMP leads to a rapid cascade of events, including 
formation of a PRR–ligand complex that can be internalized, activation of Toll‐like receptors and NFκB, 
and transcriptional activation resulting in the synthesis of reactive oxygen species, reactive nitrogen 
species, cytokines (interleukin‐1, interleukin‐12 and tumor necrosis factor‐α), and chemokines 
(interleukin-8, monocyte chemoattractant protein-1, regulated on activation, normal T cell expressed 
and secreted (RANTES)). These compounds trigger an immediate inflammatory response, and enable 
migration of additional leukocytes from the blood to the site of inflammation. CD14 is another PRR that 
is expressed on polymorphonuclear leukocytes, macrophages and monocytes. It enhances the ability of 
Toll-like receptor 4 to respond to lipopolysaccharide. The complex formed of CD14, lipopolysaccharide 
and Toll-like receptor 4 increases the production of cytokines and chemokines, leading to 
inflammation and activation of the complement cascade and the coagulation pathway. Finally, Toll-like 
receptors instruct dendritic cells to initiate a highly differentiated, specific T-cell response.14 Thus, 
defensins and PRRs not only neutralize microbial components, they also constitute an important link 
between innate and adaptive immune responses. 
Increased vascular leakage and activation of serum protein systems potentiate the local acute 
inflammatory response. Gingival crevicular fluid flows at an increased rate.108, 134 During early phases of 
lesion development, a dense polymorphonuclear leukocyte-dominated infiltrate is found in the biofilm-
adjacent gingival compartment. To destroy potential intruders, polymorphonuclear leukocytes release 
proteases, prostaglandins and other inflammation-enhancing molecules, as well as highly potent 
reactive oxygen and nitrogen species. These effectors do not discriminate between host and bacteria, 
resulting in collateral damage to gingival connective tissue. A successful inflammatory response 
eliminates the infectious agent and initiates tissue repair. However, if the infection prevails, as a result 
of persisting inflammation and instructed by macrophages and dendritic cells, cells of the adaptive 
immune system appear, and the lesion takes on chronic traits. T-cells and B-cells start to accumulate, 
and ultimately dominate the lesion. Their proportions are determined by the type of immune response 
elicited by the antigens and the presence of modulating cytokines. Plasma cells develop from B cells 
and produce antibodies in response to bacterial antigens and mitogens. In a typical gingival lesion, T 
cells predominate. T-helper cell subsets (Th1 or Th2) develop from T cells depending on the types and 
amount of cytokines released. The balance between T-helper cell subsets is critical for the 
immunoregulation of periodontal disease.356 Th1 cells predominate in stable periodontal lesions, but a 
strong presence of Th2 cells indicates a shift towards lesion progression, with a predominance of plasma 
cells.355 
The local physiological defense mechanisms are very robust and exhibit substantial redundancy. In fact, 
many people show minimal or no periodontal destruction despite experiencing gingivitis as a result of 
lifelong poor oral hygiene.234 However, robust systems are weak when their non-redundant components 
are attacked,204 resulting in deficiencies in the immune system. Such attacks may have critical 
consequences for periodontal tissue integrity, as illustrated in patients with (genetic or acquired) 
immune deficiencies. In particular, class IV.B cases of periodontal disease have been associated with 
mutations in the genes encoding for polymorphonuclear leukocyte elastase (severe congenital 
neutropenia), Chediak–Higashi syndrome 1 protein (Chediak–Higashi syndrome), integrin‐β2 
(leukocyte adhesion deficiency), cathepsin C (Papillon–Lefèvre syndrome) and others.145 
Resorption of the alveolar bone is a defining characteristic of many periodontal diseases. Several 
inflammatory pathways can result in bone destruction.387 Macrophages, in addition to processing and 
presenting antigens for activation of the specific immune response, also produce cytokines and enzymes 
that induce bone resorption. Recently, an alternative mechanism was described that involves three 
members of the tumor necrosis factor receptor family: the receptor activator of NFκB (RANK), the 
receptor activator of NFκB ligand (RANKL) and osteoprotegerin.193, 230 The ligand RANKL is found on 
osteoblasts, but is also expressed by lymphocytes present in the inflammatory infiltrate. RANK is 
expressed on mature osteoclasts and their precursors, and osteoprotegerin is synthesized by 
mesenchymal cells. The interaction of RANK and RANKL initiates the differentiation and activation of 
bone-resorbing osteoclasts, and can be blocked by the decoy ligand osteoprotegerin. RANKL and 
osteoprotegerin are found in crevicular fluid, and their relative levels appear to predict disease.54 
Epidemiology 
General trends 
Gingival and periodontal diseases occur globally and among virtually all populations that have been 
studied to date.19 Clinical signs of periodontal destruction may be absent in individuals of any age, but 
there is little evidence supporting the existence of periodontitis-resistant populations. However, two 
defined apparently resistant cohorts with no access to dental care were described in Namaqualand and 
Crossroads (South Africa).13, 324 They showed minimal clinical periodontal breakdown at any age, despite 
the presence of a heavy plaque load and gingivitis. 
The World Health Organization performed extensive surveys of the periodontal status of potentially 
under-served populations around the globe, especially in developing countries.307 Using the Community 
Periodontal Index for Treatment Needs to assess prevalence, a majority of subjects examined had 
gingivitis and 10–15% of adults had periodontal pockets ≥6 mm deep. In contrast to common belief, 
periodontal diseases are not the most important factor for tooth loss in many Asian and most African 
populations. In fact, surveys have indicated that, in Africa, most people retain the majority of their teeth 
throught their lives.43, 83 
In the USA, based on estimates obtained from the National Health and Nutrition Examinations Surveys 
performed from 1988 to 1994 (NHANES III),278 the overall prevalence of moderate to severe signs of 
periodontitis among adults was 7.3%, corresponding to one affected adult person in 14.19, 53 
Approximately one in five adults had slight periodontitis, one in ten had moderate periodontitis, and 
one in 30 showed signs of severe periodontitis. The prevalence of periodontitis increased with 
population age, but the prevalence of more severe forms peaked at 70 years and leveled off 
thereafter.19 Periodontitis was more frequently diagnosed in men than in women. Substantial racial and 
ethnical disparities were observed. Adult black people were almost twice as likely to exhibit 
periodontitis as white adults, suggesting a significant racial gap.53 
In the analysis of the more recent NHANES 1999–2000 data,53 the overall prevalence of moderate to 
severe periodontitis was only 4.2% (compared to 7.3%), suggesting a potentially substantial reduction in 
disease burden over the past decade. Surveys performed in Europe have corroborated the suspected 
‘secular trend’ of prevalence reduction in periodontal diseases among adults.334, 362 A comparison over a 
30-year period of the prevalence of various clinical signs of periodontal disease in Swedish subjects aged 
20–70 years revealed remarkable changes (Fig. 3).169 Over the surveyed period, the proportion of 
periodontally healthy individuals improved from 8% to 44%. The increment compensated for the 
decrease in the proportion of individuals with gingivitis or moderate alveolar bone loss. In contrast, the 
proportion of subjects exhibiting signs of severe periodontal disease was small and did not change over 
time. Improvements in oral hygiene, changes in lifestyle and adoption of less risky behavior, in particular 
recognition of deleterious smoking effects, have been proposed to explain the unexpected decline. 
However, much more work is undoubtedly required to confirm and understand this highly desirable 
trend. 
 
 
Figure 3. An improvement in alveolar bone index was observed over a 30‐year time period in 
Scandinavians, as indicated by the blue (1973) and red (2003) bars. Mean alveolar bone indices were 
estimated from radiographs obtained in cross‐sectional studies performed in 1973 and 2003. Age groups 
from 20 to 70 years are shown. Data from.169 
Aggressive forms of periodontitis 
Aggressive forms of periodontitis are defined by rapid localized or generalized loss of the supportive 
periodontal structures, and occur in family clusters in otherwise medically healthy subjects.221 
Aggressive forms can affect the primary or permanent dentition. Typically, susceptible patients are less 
than 30 years old at disease onset.16 The similar phenotypes of aggressive periodontal disease are 
probably the clinical expression of multiple disease forms with discrete etiologies. 
The reported prevalence of early-onset aggressive periodontitis varies from study to study. The 
comparability of the data is affected by the somewhat ambiguous disease definitions and the various 
diagnostic techniques used. A review concluded that aggressive forms of periodontitis have a low 
prevalence in most regions of the world, occurring in 0.1–1.0% of the population.20 For reasons that are 
unclear at present, this disease form is seen substantially more frequently among young black subjects. 
A prevalence of 2.6% was reported in a sample representative of high school students in the USA.15 
Even higher disease prevalences of 6.5% and 7.6% were observed in two cohorts of adolescents and 
young adults in Uganda18 and Morocco,149 respectively. These subjects were carriers 
of A. actinomycetemcomitans clone JP2, which is endemic in Morocco. Carriers of the JP2 clone, who 
were free of clinical disease signs at the first examination, had a relative risk of 18.0 (95% CI 7.8–41.2) of 
experiencing periodontal attachment loss during the 5-year observation period.150 
Although earlier reports by Saxén338 showed a female majority among subjects with early-onset 
aggressive periodontitis, a more recent national survey conducted in the USA did not corroborate this 
observation.235 Furthermore, based on the results of a genetic segregation analysis performed in 100 
families in the USA, the aggressive disease trait has an autosomal dominant inheritance pattern.249 This 
contrasts with the autosomal recessive inheritance pattern identified in northern Europe,339 suggesting a 
different pathway to disease for each of the two populations. 
 
Necrotizing periodontal diseases 
Necrotizing periodontal diseases feature ulceration and necrosis of the interdental papillae, 
spontaneous bleeding, pain and a removable pseudomembrane.4 Advanced cases involve alveolar bone 
resorption, may be generalized, and may lead to fever, malaise and lymphadenopathy.276 Necrotizing 
periodontal diseases are observed frequently in parts of Africa, Asia and Latin America, mainly in socially 
disadvantaged children. For example, in an urban South African clinic population, the prevalence of 
acute necrotizing ulcerative gingivitis was 3%. Males were more frequently affected than females. 
Seventy-three per cent of the patients were children between 5 and 12 years old. The seasonal 
occurrence varied greatly, with most cases diagnosed in the summer (relative risk 6.57; 95% CI 4.96–
8.70).28 In contrast, necrotizing periodontal disease is now rarely observed in the general population of 
Europe and North America, as confirmed in a recent study among 18- to 22-year-old military recruits in 
Switzerland.82 
A high prevalence of necrotizing periodontal disease has been observed in HIV-infected 
subjects.223, 306, 314 Based on this finding, the presence of necrotizing periodontal disease has been 
recommended for use as a surrogate marker of HIV-associated immune deficiency and AIDS.125 
Risk modifiers 
Development and progression of periodontal disease in an individual are ‘personalized’ by a number of 
endogenous and exogenous factors (Table 4). Assessment, knowledge and proper management of these 
factors facilitate the prevention of disease or its containment in the case of an existing periodontal 
condition. An intelligent algorithm that estimates the risk for periodontal disease based on easily 
accessible clinical information was developed, validated and implemented in practice.299, 301 
Table 4.  A selection of risk modifiers of chronic and aggressive periodontitis 
Risk modifier 
 Age of patient 
 Bleeding on probing 
 Diabetes mellitus 
 Furcation involvement 
 History of periodontal surgery 
 Probing (pocket) depth 
 Radiographic bone level 
 Restoration below the gingival margin 
 Root calculus 
 Single-nucleotide polymorphisms 
 Smoking history 
 Vertical bone lesions 
 
Smoking 
An association between smoking and alveolar bone loss was first reported by Waerhaug’s group in the 
late 1950s.31 Cigarette smoking was identified to be an age-independent risk indicator for periodontal 
disease in the Tecumseh Community Health Study in Michigan.378 This greatly increased risk of smokers 
experiencing periodontal breakdown was confirmed in many studies.36, 104, 163, 255, 315 An analysis of the 
NHANES III survey data concluded that smokers have a four times greater risk of periodontitis than 
non-smokers.17 The data suggest a dose–effect relationship between the number of cigarettes smoked 
per day and the likelihood of developing periodontitis. The research further estimated that more than 
40% of cases of periodontitis among adults can be attributed to current cigarette smoking. Of major 
clinical relevance is the observation that smoking impairs wound healing following scaling and root 
planning,137, 182, 403 periodontal surgery24, 111, 376, 396 and guided tissue regeneration procedures.240 
Mechanisms for smoking-induced adverse effects have been postulated, but the precise molecular 
pathways remain to be identified.46, 49 Smoking is unquestionably a major risk modifier for most 
inflammatory periodontal diseases. 
Genetics 
It has been well established from twin studies that genetic factors contribute substantially to the risk of 
chronic periodontitis.84, 266, 267 A population-based study275 in more than 10,000 Swedish twin pairs 
estimated that genetics-attributable contributions to the cummulative risk of periodontal disease 
amounted to 39% (95% CI 31–47%) and 33% (95% CI 24–42%) in women and men, respectively. 
Furthermore, the magnitude of the effect was strongly influenced by age and smoking status, suggesting 
substantial gene–environment interaction. 
Based on the currently available evidence, chronic and aggressive forms of periodontitis are not 
associated with single gene mutations or acquired molecular abnormalities. However, DNA sequence 
variations in genes that result from alteration of a single nucleotide can substantially affect the disease 
phenotype. Single-nucleotide polymorphisms are thought to play a role in periodontal diseases.10 The 
commercial availability of high-throughput, low-cost technology has boosted research in genome-based 
risk factors for complex diseases. As a result, the association of numerous polymorphisms with specific 
forms of periodontal disease was investigated.58, 114, 120, 130, 181, 208, 380, 383, 422, 423 Examples of single-
nucleotide polymorphisms that were considered in such studies include those in interleukin-1, 
interleukin‐6, interleukin‐10, interleukin‐12RB2, Fc‐γ, matrix metalloproteinase‐9 and tumor necrosis 
factor‐α, to name but a few. In addition to obtaining a better understanding of the disease process, such 
polymorphisms may be used as diagnostic or prognostic markers. The PST™ genetic test (Interleukin 
Genetics Inc., Waltham, MA, USA) has been offered to patients with periodontitis. It tests for single-
nucleotide polymorphisms of interleukin-1 genes, and has shown moderate sensitivity and specificity in 
predicting disease progression in non-smokers. The test’s cost-effectiveness was investigated using a 
mathematical model.160 The authors’ conclusion that more benefits would result if risk-specific 
treatments were available is very much to the point. 
Epigenetic alterations to the genome may also play a significant role in disease expression. These 
changes involve both methylation of DNA and post-translational modification of histone proteins. The 
epigenetic profile is modified by the environment over time, and may have substantial implications for 
periodontal disease expression.421 
Diabetes 
Estimates suggest that approximately 7% of the total population in the USA have diabetes, and the 
prevalence is increasing.66 Subjects with a history of type 2 diabetes mellitus have a higher prevalence 
and severity of periodontitis, as shown in Pima Indians.110 In another study, 25- to 74-year-old diabetics 
had significantly increased likelihood of experiencing attachment loss.136 Recently, an increased 
prevalence of periodontitis was shown in children and teenagers with type 1 diabetes compared to 
age-matched controls.217 Subjects with poor glycemic control showed faster recurrence of periodontal 
pockets after periodontal treatment than non-diabetic controls.389 Westfelt et al.416 compared the 
outcomes of periodontal surgical treatment in subjects with well-controlled type 1 and 2 diabetes with 
those in sex- and age-matched controls over a 5-year period. All subjects had moderate to advanced 
forms of chronic periodontitis. The results showed no difference between the two treatment groups, 
suggesting that well-controlled diabetics can maintain healthy periodontal conditions. There has been 
increased interest in the question of whether or not treatment of periodontal diseases leads to 
improved glycemic control in diabetic patients.178 Nine controlled clinical trials were performed in an 
attempt to answer this important question, and the results were summarized meta-analytically.94 The 
overall results indicated that periodontal treatment led to a statistically significant reduction in the 
surrogate marker glycosylated hemoglobin (HbA1c). However, the authors’ enthusiasm about this 
favorable finding was guarded because of the small size of the reduction (<1%) and its lack of 
robustness. They therefore concluded that there is still insufficient evidence for global recommendation 
of periodontal treatment as an effective measure to reduce glycosylated hemoglobin (HbA1c) in adult 
subjects. 
Obesity 
Obesity is a major risk contributor to disease and death worldwide. More than 60% of adults in the USA 
are overweight, and approximately 30% are obese.151 Close relationships have been established 
between obesity and diabetes, hypertension, coronary heart disease and stroke, and cancer.146 Body fat, 
which is accumulated to excess in obese people, is produced by adipocytes. In addition to producing fat, 
these cells also release molecules that affect insulin resistance, and secrete hormones and cytokines, 
leading to a hyperinflammatory state. In a brief editorial note, Saito et al.336 described their observation 
that apparently healthy Japanese subjects with a BMI > 25 kg/m2 had a significantly higher relative 
risk of periodontitis than subjects with a BMI < 20 kg/m2. The association between obesity and 
periodontitis was subsequently substantiated by more extensive studies in various populations.227, 310, 424 
Pregnancy 
The female body is subject to substantial hormonal fluctuations, especially during pregnancy. The most 
remarkable hormonal change during pregnancy is the increasing production of estrogens and 
progesterone, which levels off approximately one month before delivery. By that time, estrogen blood 
levels have risen more than 100-fold. In addition, the type of estrogen secreted changes from estradiol 
to the less potent estriol. These hormones are mostly produced by the placenta, and the levels revert to 
pre-pregnancy levels within a few days after delivery. An increased prevalence and severity of gingival 
inflammation were reported in pregnant women.231, 247, 375 These changes appear to be independent of 
changes in plaque amount168 and are reversible.140 About one pregnant woman in 20 develops a highly 
vascular, edematous lesion known as pyogenic granuloma. The lesion occurs typically during the first 
two trimesters, and has a strong tendency to recur if excised during pregnancy. Although hormones are 
likely to play a significant role in the development of pyogenic granuloma, its etiology remains largely 
unknown.216 
Medications 
Early studies on the effect of oral contraceptives on parameters of periodontal health reported an 
increased prevalence and severity of gingivitis in subjects who were taking contraceptives than in 
controls.250 The contraceptives used by study participants contained high doses of estrogen, progestin, 
or both. In contrast, the most frequently used products at the present time are low-dose combination 
preparations of estrogen (≤50 μg) and progestin (≤1 mg). A more recent study382 used information 
collected in NHANES I and III to investigate the relationship between oral contraception use and 
periodontal parameters. The thorough analysis rejected the previously held notion that women on oral 
contraception are at higher risk of experiencing clinical signs of gingivitis or periodontitis. 
Certain anticonvulsants (e.g. phenytoin), immunosuppressants (cyclosporine) and calcium channel 
blockers (e.g. nifedipine) have been associated with gingival enlargement.7 The prevalence of this side-
effect varies from 5% to 50% in adults.79 For cyclosporine, the highest prevalence of gingival overgrowth 
was observed in children191 and decreased with increasing patient age.152 The severity ranged from small 
single lesions to massive growths that impaired function and esthetics.147 The pathogenesis of drug-
influenced gingival enlargement remains unresolved, although a multitude of contributing factors 
appear to be involved, including integrins, cytokines and matrix metalloproteinases. An interesting 
hypothesis proposed involvement of single-nucleotide polymorphisms of the MDR1 gene, which 
encodes the drug-efflux pump P-glycoprotein. This effect was observed in a clinical study98 that found 
severe cyclosporine-induced overgrowth in patients carrying the MDR1 C3435T mutation. 
Nutrition 
For many centuries, a deficient diet was considered a cardinal factor in the development of periodontal 
diseases. The hypothesis was based on anecdotal evidence, and held up to its premise until animal 
experiments permitted its scientific test. Glickman126 was among the first to investigate the effect of 
vitamin C on the periodontium in guinea pigs. His experiments confirmed that diets lacking certain 
vitamins or minerals can affect the development of periodontal tissues and bone. Specifically, the 
author concluded that a diet deficient in vitamin C resulted in generalized alveolar changes but was 
not responsible for periodontal pocket formation. Recently, Nishida et al.284 reassessed the relationship 
between dietary vitamin C intake and periodontal disease using the powerful NHANES III database. 
They found that persons with low vitamin C intake (<30 mg/day) had a slightly increased likelihood of 
developing periodontitis when compared to a reference group with elevated intake (>180 mg/day). 
Diets rich in whole grain have been associated with lower risk of diabetes and cardiovascular disease.226 
This desirable effect is probably the result of improved insulin sensitivity and improved glycemic 
control.180 Merchant et al.262 used information gathered in the Health Professionals Follow-up Study 
(HPFS) to investigate the relationship between intake of whole grain, refined grain or cereal fiber and 
risk of periodontitis. After 14 years of follow-up, men who consumed 3.4 servings per day (median) of 
whole grains were 23% less likely to be diagnosed with periodontal disease than those who consumed 
0.3 servings per day (median). These intriguing results were further confirmed in a study using data from 
NHANES III that found an inverse association between serum total antioxidant capacity and 
periodontitis.69, 70 
Systemic effects of periodontal disease 
After several decades of relative absence from the scientific literature, new reports linking indicators of 
dental health with an increased risk for a variety of systemic diseases emerged in the 1980s and 1990s. 
Examples include associations with myocardial infarction.257, 361 stroke,236, 381 cardiovascular disease,102 
peripheral vascular disease,261 adverse pregnancy outcomes95, 289 and pneumonia.118, 340, 341 The 
possibility that periodontal and other diseases of the human body could be linked created broad-based 
excitement among the dental community and beyond, and ushered in the era of periodontal 
medicine.418 As a result, in a worldwide effort, hundreds of clinical and laboratory studies have been 
performed, leading to a much deeper understanding of periodontal diseases as part of overall health. 
The foundation for an etiological role of periodontal diseases in general health is based on two 
assumptions. First, bacteria released from biofilms located in periodontal pockets can enter the 
bloodstream through ulcerations of the pocket epithelium and colonize other body parts, especially in 
patients with compromised immunity.200, 342 Second, periodontal pathogens elicit inflammatory 
reactions in the affected tissues, stimulating the release of pro-inflammatory cytokines or acute-phase 
proteins, and contributing to systemic inflammation, possibly atherogenesis, and other 
pathology.96, 200, 303 
Although many published (frequently small-scale) studies have reported statistical associations between 
parameters of oral health and systemic disease, the all-important cause/effect relationship awaits 
confirmation in large-scale longitudinal epidemiological and interventional studies. Examinations of the 
link between periodontitis and coronary heart disease using information collected in NHANES I did not 
show the expected strong association.171, 172 Furthermore, a review of nine cohort studies found no or 
only weak associations after controlling for smoking or lifestyle factors.174 The concern that confounding 
could mask the study outcome received additional support in the 6-month pilot trial of the National 
Institutes of Health-sponsored Periodontitis and Vascular Events (PAVE) study.293 The trial showed that a 
beneficial effect of periodontal treatment on the surrogate marker hs-C-reactive protein was achieved 
only in non-obese subjects with cardiovascular disease, whereas it was not observed in obese subjects. 
Another National Institutes of Health-funded multi-centered study, the randomized controlled 
Obstetrics and Periodontal Therapy (OPT) trial, investigated the effect of non-surgical periodontal 
treatment on pre-term birth rates in more than 800 pregnant women exhibiting clinical signs of chronic 
periodontitis.268 The investigation confirmed the safety and effectiveness of standard periodontal 
treatment in pregnant women, but did not detect significant treatment-induced reductions in the rate of 
pre-term birth or other birth-related outcomes. 
It is too soon to draw a final conclusion as to whether the so-called ‘systemic link’ is of major public 
health relevance, or not. Caution is warranted. The biological plausibility model of the systemic link 
assumes that the larger the wound surface area, the greater the chances of bacteremia, and that the 
large wound surface persists over substantial time periods. Are some of the model assumptions overly 
optimistic? For example, the combined contact surface area between biofilms and pocket epithelium in 
patients with generalized periodontitis was estimated as up to 70 cm2,297 potentially resulting in an 
impressively large wound surface.290 However, the overwhelming majority of patients with chronic 
periodontitis do not show signs of disease activity in all pockets simultaneously,364 and phases of such 
activity are typically short-term. Indeed, detection of active periodontal disease is a daunting task in 
most patients because of its elusive character. The disease is often present at only a few sites, which 
could mean that the effective wound size is considerably smaller than previously estimated, possibly just 
a few square centimeters.173, 282 Although not impossible, detection of remote effects of such a small 
wound is a formidable challenge. 
Treatment modalities for gingivitis and periodontitis 
Historical overview 
Local mechanical debridement of the teeth and root surfaces has been advocated for centuries as a 
treatment for diseases of the periodontium, with descriptions of calculus removal being found in the 
ancient writings of almost all known civilizations. Various other therapies such as cauterization using 
thermal or chemical agents, use of astringents on the soft and hard tissues, as well as soft-tissue 
removal using curettes or surgical blades have been advocated at various times and in various cultures 
as treatments for periodontal diseases.127, 128 Scientific and technical progress in the 19th and 20th 
centuries, including better understanding of the histopathology of the disease and its microbial etiology, 
as well as the development of radiography, local anesthesia and analgesia, made diagnosis and 
treatment of periodontal diseases more standardized although not truly cause-related. 
After the seminal work by Löe et al.,232 demonstrating the cause and effect relationship between 
bacterial plaque/biofilms and gingival inflammation, the second half of the 20th century saw an 
explosion of research on cause-related therapy for gingivitis and the most common phenotypes of 
periodontitis. These centered on mechanical and chemical methods to attack the microbial origins of 
disease. Later observations of differential host susceptibility to disease162, 234 and the discovery of 
molecular mechanisms of tissue destruction in the periodontium243 suggested anti-inflammatory or host 
modulation approaches as potential means to address periodontal syndromes.202 Today it is universally 
agreed that effective periodontal therapy for plaque-related disease requires elimination of 
inflammation through re-establishment of a biologically acceptable ‘clean’ root surface. Current 
therapeutic approaches all aim to achieve that end with minimal removal of cementum. Antimicrobials 
and host-modulating agents may be used as adjuncts to this basic and arguably ancient mechanical 
approach to therapy. How, when and why these approaches fit into therapy is discussed below in the 
context of treatment sequence, with emphasis on the most common form of disease: chronic 
periodontitis. 
Systemic and acute phases of treatment 
General guidelines for dental treatment planning have been published377 based on five treatment 
phases: systemic, acute, cause-related, surgical corrective and maintenance (Table 5). The systemic 
treatment phase is concerned with prevention of treatment complications, particularly in subjects in 
whom periodontitis is associated with systemic disease, as well as with protection against disease 
transmission. Another goal of the systemic phase is to optimize treatment outcomes by addressing 
important subject-based risk factors, such as smoking163, 315 and diabetes.389, 416 Although the systemic 
treatment phase is crucial in many periodontal disease phenotypes, the acute treatment phase is usually 
only implemented for symptomatic forms of periodontal disease, such as necrotizing periodontal 
diseases, abscesses of the periodontium, and sometimes in cases of periodontitis associated with 
endodontic lesions. In acute situations, the systemic treatment phase may be abbreviated, but cannot 
be ignored. For such situations, control of pain and infection is paramount. Basic treatment approaches 
for some common acute periodontal conditions are outlined in Fig. 4. As the majority of gingivitis and 
tissue-destructive periodontal diseases are non-painful, most of the treatment for these conditions 
occurs in the context of overall restoration of oral health during the active treatment phases. 
Table 5.  Guidelines for sequencing the treatment for periodontal patients. Modified and reproduced 
with permission from377 
I: Systemic phase 
 A Consultation with patient’s physician 
 B Pre-medication 
 C Stress/fear management 
 D Any necessary treatment considerations for systemic disease 
II: Acute phase 
 A Emergency treatment for pain and infection 
 B Addressing the urgent chief complaint 
III: Cause-related phase 
 A Oral hygiene education, patient motivation and risk assessment 
 B Mutual goal-setting for acceptable outcomes/endpoints of therapy 
  i: Implementation of strategies for risk reduction 
 C Excavation of deep carious lesions 
  i: Determine restorability 
 D Extraction of hopeless teeth along with non-surgical periodontal debridement 
 E Removal of plaque retentive factors 
 F Necessary endodontic and occlusal therapy 
 G Post-treatment re-evaluation 
  i: Objective assessment of endpoints of therapy 
IV: Surgical corrective phase 
 A Resective/regenerative and implant surgical procedures 
 B Post-surgical re-evaluation 
  i: Objective assessment of endpoints of therapy 
 C Definitive prosthodontic restoration 
V: Maintenance phase 
 A Periodic professional supportive care 
 B Reinforcement of oral hygiene instruction and motivation 
 C Annual multi-pronged periodontal stability and risk re-assessment 
 D Comprehensive professional supra- and subgingival plaque removal 
 E Radiographic updates and therapeutic interventions (as needed) 
 
 
Figure 4. Common treatment strategies for acute periodontal conditions. ANUG: acute, necrotizing, 
ulcerative gingivitis. ANUP: acute, necrotizing, ulcerative periodontitis. PRN: as needed. BID: twice a day. 
Active treatment and maintenance 
Periodontal treatment is often divided into disease control, surgical and maintenance phases. While 
variations in the therapeutic approach are necessary for different forms of periodontal disease, these 
three phases are generally applicable to asymptomatic periodontitis patients. The disease control phase 
has also been termed the ‘initial’ or ‘cause-related’ phase of treatment because it is primarily focused on 
elimination of pathogenic subgingival biofilms as well as removal of factors that promote biofilm 
formation and subsequent destructive inflammation. An overview of common treatment strategies for 
gingivitis is presented in Fig. 5. For plaque-induced gingivitis, the treatment centers on professional and 
personal plaque removal, with proper training in needs-related oral hygiene measures being critical. 
Antiseptics can also play a role in reducing plaque and gingivitis. For non-plaque-induced gingivitis, it is 
important to identify the source of inflammation and reduce or eliminate it whenever possible. Common 
treatment approaches for chronic and aggressive periodontitis, in which tissue destruction has occurred, 
are outlined in Fig. 6. In each case, active treatment centers on disruption of the pathogenic biofilm by 
non-surgical mechanical debridement using antimicrobial and sometimes anti-inflammatory adjuncts, 
and, as with all biofilm-mediated oral disease, patient-specific instruction in daily plaque removal. 
 
Figure 5. Common treatment strategies for gingivitis. BID: twice a day. 
 
Figure 6. Comparison of active treatment strategies for chronic and aggressive periodontitis. 
While traumatic occlusion is not an etiological factor for periodontal disease, it is considered to be a 
potential disease modifier. It is often addressed during initial therapy.5 Management of other potential 
disease modifiers, such as psychological stress, osteoporosis and poor dietary habits, is often advocated. 
Such interventions can be beneficial. However, little research has been performed to clarify the effects 
of these other potential risk indicators on disease susceptibility, and even less research has been 
performed regarding intervention.155 
Success in the cause-related phase is achieved when disease progression is halted or significantly 
reduced, as determined by measurements taken upon re-evaluation (Table 6). Important clinical 
benchmarks for assessment of treatment success include reduction in bleeding on probing and probing 
depth, together with gains in clinical attachment levels and optimization of needs-related plaque 
control. There is insufficient evidence to support the utility of microbial diagnostics as a tool in the 
management of chronic periodontitis, although microbial assessment may play a useful role in guiding 
therapy for aggressive periodontitis and phenotypes of disease that are non-responsive to conventional 
therapy.237 
Table 6.  Prediction of periodontal stability defined as a change in clinical attachment level of 0 ± 1 
mm and no change in radiological bone level 
Predictor Level Decision criterion Long-term stability Reference 
Diabetes (HbA1c) Patient HbA1c ≥ 9% (poor control) Unfavorable 388 
Obesity (BMI) Patient BMI ≥ 30 kg/m2 Unfavorable 310 
Smoking Patient Current smoker Unfavorable 258, 316, 396 
Oral hygiene (HI) Full 
mouth 
HI>30% consistently Unfavorable 41 
Radiographs Site Crestal lamina dura consistently 
present 
Favorable 322 
Site Loss in crestal bone height Unfavorable 322 
Bleeding on probing Site Bleeding on probing = 0 
consistently 
Favorable 185, 220 
Site Bleeding on probing > 0 
consistently 
Questionable 41, 76, 219 
Full 
mouth 
Bleeding on probing > 30% 
consistently 
Unfavorable 185 
Gingival inflammation 
(GI) 
Tooth All tooth sites GI ≤ 1 consistently Favorable 222 
Tooth All tooth sites 1 < GI ≤ 2 
consistently 
Questionable 222 
Tooth All tooth sites GI ≥ 2 consistently Unfavorable 222 
Predictor Level Decision criterion Long-term stability Reference 
Probing depth (PD) Site Change in PD = 0 ± 1 mm Favorable 41, 75, 76 
Site Change in PD ≥ 2 mm since 
previous visit 
Unfavorable 41, 75, 76 
Site Eight or more sites with PD ≥ 5 
mm 
Unfavorable 76, 258 
Site PD ≥ 6 mm Unfavorable 258 
For definitions of long-term stability criteria, see.215 
The surgical/corrective phase of therapy is performed only after thorough re-evaluation of initial 
therapy has suggested that residual infection/inflammation exists, and compliant patients are still at risk 
for disease progression (Fig. 6). In the surgical phase of therapy, periodontal regeneration or resection 
may be attempted, depending on the bone and soft-tissue architecture. Useful treatment algorithms 
have been published recently and will not be detailed here.190 A combination of resective and 
regenerative procedures is often used at a single surgical site (Fig. 7). However, surgical therapy is best 
avoided in patients whose plaque control is inadequate228, 287 or who are heavy smokers.316 
 
Figure 7. Periodontal surgical intervention for severe chronic periodontitis that combines resective and 
regenerative strategies to reduce pocket depth and achieve a healthy and maintainable periodontium. 
(A) Chronic periodontal abscess showing exudate on palpation of teeth 24 and 25. (B) Probing confirms a 
12 mm mucogingival/osseous defect. (C) Pre‐treatment periapical radiograph showing advanced bone 
loss. (D) Surgical flap after defect and root debridement and prior to bone graft and Emdogain®. (E) The 
tissues have been positioned apically and sutured. (F) Probing depths are stable and maintainable. (G) 
Healthy but receded gingival tissues are seen five years after treatment. (H) Periapical radiograph 
suggesting some improvement in bone level after 5 years. 
The supportive or maintenance phase of therapy involves secondary prevention of periodontal disease.3 
Ideally, this phase is entered only after all signs of disease have been eliminated or substantially reduced 
and the long-term stability of periodontal health is highly probable. A multi-pronged approach to regular 
reassessment of periodontal health during the supportive phase is critical to long-term success in 
preventing disease recurrence (Table 6).100 Although absence of bleeding on probing is a useful indicator 
of health,220 increasing pocket depth over time, or pockets deeper than 6 mm coupled with consistent 
bleeding on probing, are still the best predictors of disease progression.41, 75, 258 These measures have 
been proven useful and are easy to record, and so have become important clinically.398 Recently, 
Offenbacher et al.291, 292 proposed what they call the ‘biofilm–gingival interface classification’, based on 
classic clinical disease markers coupled with microbial and host molecular markers for disease, to 
describe different biological phenotypes of periodontitis. The molecular markers may turn out to be 
useful adjuncts to the standard clinical markers of probing depth and bleeding on probing. 
Efforts continue in the hope of developing saliva- or crevicular fluid-based diagnostic systems that may 
help to distinguish between health and disease based on microbial or host inflammatory markers.54 As 
yet, no system is in wide use, perhaps due to the fact that detailed multi-pronged clinical observations 
continue to be very effective. 
Non-surgical cause-related treatment 
Plaque control 
The first step in treatment of any form of periodontitis is training the patient in proper plaque removal. 
Although effective oral hygiene provides limited but positive changes in signs of disease, such as 
reductions in probing depths and bleeding on probing,39, 40, 67, 238 optimal daily plaque control is the most 
important determinant for long-term success in periodontal therapy.35, 38, 354 A systematic review on the 
effects of a prophylaxis combined with a single episode of oral hygiene instruction emphasizing use of a 
manual toothbrush demonstrated a small but consistent reduction in gingivitis, even though it was clear 
that plaque reduction in these studies was not optimal.405 More focused training in needs-related plaque 
removal, such as flossing, the use of woodsticks or other interdental hygiene aids, can be extremely 
effective in reducing disease long-term when combined with regular professional mechanical 
cleaning.33, 34, 38, 210 Combining interdental plaque removal with an already existing habit of 
toothbrushing has been strongly advocated.37 
Powered toothbrushes have been shown in systematic reviews to provide a modest additional short-
term benefit over manual toothbrushing.330, 359 Compliance is an issue over the long-term, and even the 
best powered brushes have yet to demonstrate clinically relevant proximal plaque removal. It is clear 
that repeated instruction and motivation on interdental cleaning by any means is necessary for long-
term success, particularly in the high-risk posterior teeth.369, 370 When interproximal soft tissue has 
receded, use of interdental brushes is of particular value.72, 197, 409 
Removing plaque-retentive factors 
The removal of plaque-retentive factors as part of initial periodontal therapy is clearly important. 
Multiple retrospective cross-sectional studies as well as short-term longitudinal studies have confirmed 
the negative microbiological and clinical effects of subgingival and otherwise non-ideal restoration 
margins.294 
Scaling and root planing 
Mechanical root cleaning as a treatment for periodontitis has been advocated for centuries, and scaling 
and root planing is still the ‘gold standard’ treatment for chronic periodontitis. This cause-related 
approach is aimed at removal of pathogenic biofilms, toxins and calculus, and re-establishment of a 
biologically acceptable root surface. Shrinkage of the periodontal pocket occurs as a combination of soft 
tissue reattachment to the clean root surface and recession of the soft-tissue margin as a result of a 
decrease in the inflammatory infiltrate in the periodontal tissues.39, 40 Significant reductions in the levels 
of motile rods and spirochetes are a common finding in areas that show clinical improvements after 
treatment.142, 161, 327 Evidence for clinical improvement includes positive changes in tissue color, contour 
and consistency, as well as in reductions of bleeding on probing and pocket depth, and gain in 
attachment. 
Badersten et al.40 proposed that, for non-molar teeth, there is no true threshold pocket depth where 
non-surgical periodontal therapy becomes ineffective. However, others have suggested that the ability 
to adequately remove biofilm and calculus to achieve a biologically acceptable root surface depends on 
the depth of the pocket, the root anatomy, the instrumentation, the experience of the operator and the 
approach used.57, 61, 62, 106, 116, 374 Systematic reviews have indicated that powered instruments, such as 
magnetostrictive and piezoelectric ultrasonic scalers and sonic scalers, are at least as effective as 
curettes in mechanical debridement, but the powered instruments tend to be more efficient.402, 414 
There is some evidence that powered instruments may be more effective in areas that are difficult to 
access, such as furcations and deeper pockets.50, 256 When used properly, the powered instruments 
appear to remove less root structure.346 
Adjunctive treatments during initial-phase therapy 
Systemic antibiotics 
Use of systemic antibiotics as an adjunct to scaling and root planing has become the standard of care in 
aggressive and non-responsive forms of periodontitis. However, the decision to use a systemic antibiotic 
must be made based on the patient’s medical and dental history. Performing microbial culture and 
obtaining antibiotic sensitivity data are recommended.8 
Systemic antimicrobials have also shown some benefit with regard to clinical attachment level gains in 
short-term treatment studies of chronic and aggressive periodontitis, with the benefit being more 
pronounced in deeper sites.141, 142 However, as mechanical treatment alone is quite often effective, and 
development of antibiotic-resistant bacterial strains is a growing problem, widespread use of such 
adjunctive therapy for chronic periodontitis cannot be justified.141, 411 Many systemic antimicrobials and 
combinations of agents were tested in clinical trials, with tetracyclines, metronidazole and combinations 
of metronidazole with amoxicillin being most frequently reported.141 Systemic use of antibiotics as an 
adjunct to non-surgical periodontal therapy may have at least a short-term positive effect on systemic 
levels of inflammation.352 and on glycemic control in diabetics.138 
Local antimicrobial treatment 
The delivery of high levels of antimicrobial directly to the disease site has advantages over systemic 
antibiotics, including fewer side-effects and non-compliance issues. Several systems have been 
approved by the Food and Drug Administration for use in the USA, and in other countries. By and large, 
systems showing ease of use, consistent retention at the site of placement, and slow, steady release of 
high concentrations of antimicrobial have become popular adjunctive therapies. Non-setting gel 
preparations have fared poorly, presumably due to unfavorable release characteristics.87, 392 Several 
large randomized, multi-center clinical trials have demonstrated modest short-term clinical benefits of 
antimicrobials as an adjunct to scaling and root planning.107, 109, 179, 419 Test agents with favorable 
pharmacodynamics included tetracycline fibers, chlorhexidine chips, minocycline microspheres and 
doxycycline gel. Their use in the initial stage of therapy has shown statistically significant improvements 
in probing depth reduction, and clinical attachment level gains in some cases. However, reviews have 
suggested that the magnitude of the changes is of questionable clinical relevance.52, 88, 133, 144 Moreover, 
the cost/benefit ratio remains unproven.99, 158 Currently, the most accepted indication for local 
antimicrobial treatment is in chronic periodontitis patients with isolated pockets of moderate disease 
that have not responded to mechanical therapy alone (Fig. 6).11 
Recent trials using locally delivered minocycline microspheres as part of ‘intensive periodontal therapy’ 
demonstrated short-term alterations in several systemic inflammatory markers in addition to providing 
local clinical benefits that lasted for several months.92, 399 
Host modulation 
The concept of modulating the inflammatory response as a way to reduce or prevent periodontal 
breakdown has been investigated since Golub et al. observed that minocycline inhibited collagenase 
activity in a germ-free rat model.129 As periodontal bone and attachment loss are the result of 
destructive inflammation, it stands to reason that a reduction of the host response should provide a 
useful adjunct to typical mechanical and chemical antimicrobial approaches during disease control or 
maintenance phases of treatment (Fig. 6). Host modulation approaches have been based primarily on 
damping down effector molecules such as matrix metalloproteinases and prostanoids, although more 
recent efforts to inhibit destructive inflammation have targeted upstream mediators, such as p38 MAPK 
(203), as well as novel downstream lipid mediators, lipoxins and resolvins, that actually appear to 
resolve the chronic inflammatory response rather than simply suppress it.148, 407, 408 An additional 
approach, focused on alterations of bone metabolism by bisphosphonates, has also been studied.124 
While studies of non-steroidal anti-inflammatory drugs, bisphosphonates, and most recently p38MAPK 
inhibitors, lipoxins and resolvins, have shown proof of concept, only low-dose doxycycline has obtained 
US Food and Drug Administration approval for treatment of periodontal disease. In several large, 
randomized multi-center clinical trials, investigators demonstrated modest clinical benefits with 
adjunctive low-dose doxycycline after scaling and root planing in subjects with moderate to severe 
generalized chronic periodontitis.64, 286, 317 In addition, a systematic review concluded that adjunctive use 
of low-dose doxycycline, together with non-surgical scaling and root planing, provided a statistically 
significant improvement over non-surgical therapy alone.325 However, the clinical relevance of the 
adjunctive benefits demonstrated for this therapy has been questioned.133 Moreover, compliance is 
always an issue when patients are required to take frequent medication for prolonged periods of time, 
and a modified version of low-dose doxycycline (40 mg everyday) was introduced in response to such 
issues.319 Controversy remains regarding the effect of low-dose doxycycline in smokers.280, 318 From a 
microbiological viewpoint, there is a growing body of evidence suggesting that the standard regimen 
low-dose doxycycline (20 mg twice a day) has no detrimental effects on the commensal flora of the 
oral cavity or the gastrointestinal tract.391, 412, 413 
However, caution remains regarding application of low-dose doxycycline. Matrix metalloproteinases are 
ubiquitous and necessary for normal physiological processes, and the potential consequences of long-
term matrix metalloproteinase inhibition on other systems are not yet clear. Host modulation 
therapeutic agents under development show promise, but a magic bullet isn’t on the horizon.202, 203, 408 
Further advances in this area of therapy await better classification of diseases and identification of the 
multi-faceted molecular basis for the biofilm/host imbalances that produce destructive inflammation. A 
glimpse into the future was provided by the observation that use of resolvins, but not aspirin-triggered 
lipoxins, have a positive effect on human neutrophils from subjects with localized aggressive 
periodontitis, and that topical resolvins reverse periodontal inflammation in the rabbit periodontal 
disease model.148 Scientists have expressed great hope in pharmacogenomics,121 in which the individual 
genetic and epigenetic make-up of the patient will guide efforts to modulate the host response via drugs 
and even diet. DNA microarray analysis will be useful in this endeavor.209 Using these molecular 
approaches, we may finally begin to develop individualized therapies with predictable outcomes for 
various periodontal diseases. 
Full-mouth disinfection 
The concept of same-day full-mouth ‘disinfection’ (antisepsis) was introduced in 1995320 as a potentially 
more effective non-surgical periodontal therapy than the conventional quadrant-by-quadrant scaling 
approach. Many follow-up studies have been performed, with varied results.25, 26, 205, 273 The idea of 
radically reducing the levels of bacterial pathogens from all intra-oral niches, including the gingival 
crevice and periodontal pockets, is conceptually sound. However, variations in study designs have 
prevented a clear answer as to whether the concept will effectively translate into a widely accepted 
clinical approach. The pertinent evidence was assessed at the 6th European Workshop of 
Periodontology. The reviewers concluded that full-mouth scaling and root planing with or without 
adjunctive antiseptics does not provide significant clinical benefit beyond conventional, staged 
debridement. It was concluded that any of the three treatment approaches are valid ways to accomplish 
debridement in the cause-related treatment phase for chronic periodontitis.337 
Lasers 
The use of laser light to disinfect the periodontal pocket more efficiently has been another area of 
intense research.22, 90, 393 A recent review of the available evidence80 concluded that results are 
inconsistent, and that the radiation parameters and techniques have not been reported in enough detail 
to make useful recommendations. According to Schwartz et al.,349 use of the Er-YAG laser as a 
monotherapy may be useful in the cause-related phase of therapy, as it appears to provide similar 
clinical outcomes to conventional mechanical debridement, but the evidence is weak. Other lasers such 
as the CO2, Nd:YAG and Nd:YAP lasers have higher potential for thermal damage to the root surface, and 
have not shown a clinical benefit, and as such are not recommended.337 The technology appears to 
require more development and testing before it can be considered a substitute for classic mechanical 
debridement.80 
Photodynamic therapy is another technology of great potential.184 The essence of photodynamic 
therapy is to load bacteria with a photoreactive dye, such as toluidine blue, and subsequently expose 
the dye–bacteria complex to tissue-penetrating light. The combination of dye and light energy leads to 
formation of singlet oxygen reactive species that can cause cell death. Photodynamic therapy could be 
an interesting adjunct to scaling and root planing, but this approach is still in development.23, 97 
Surgical phase of treatment 
When therapeutic targets are not achieved following appropriate cause-related treatment, a surgical 
approach may be indicated (Fig. 6). Several surgical procedures have been well documented as a means 
to gain access to facilitate instrumentation of the root surfaces, reducing pocket depths and restoring 
clinical attachment. These surgical approaches have been utilized in treatment of periodontal disease 
for decades, and are broadly classified as access, resective or regenerative procedures. The pocket 
depth and bone architecture will dictate which surgical approach is indicated. 
Access treatment 
There have been vigorous debates over the past century concerning the relative merits of surgical and 
non-surgical treatment for periodontitis.128 In the 1980s, several groups published longitudinal clinical 
trials comparing scaling and root planing to various surgical procedures with or without osseous re-
contouring. In general, the non-surgical treatments compared reasonably well to more invasive 
approaches when surrogate outcomes, such as change in probing depth and clinical attachment level, 
were used.186-188, 228, 308, 321 Unfortunately, the vast majority of these trials used a split-mouth design, 
which has serious deficiences, including carry-across effects.101, 170, 225 This design is no longer 
recommended for comparative efficacy studies of periodontal treatments. 
A more recent 12-year, randomized, parallel-group clinical trial compared scaling and root planing to 
surgical access. It showed that surgical access resulted in fewer teeth being lost over time as well as 
fewer subjects showing continued disease progression. This was particularly evident over the first three 
years of the study.354 Over this period, approximately 80% of the subjects who received only scaling and 
root planing reached a stable endpoint, while 20% continued to show signs of significant clinical 
attachment loss. However, recognizing the 20% of patients who do not reach a stable endpoint after 
non-surgical therapy remains a formidable challenge for the clinician. In addition, the study only 
assessed single-rooted teeth,354 and did not consider the more difficult furcation areas in multi-rooted 
teeth. 
Resective procedures 
Resective procedures are designed to reduce or eliminate periodontal probing depths and establish 
favorable gingival and osseous contours that will allow more efficient oral hygiene and periodontal 
maintenance. Two soft tissue resective procedures that have been employed in periodontal treatment 
for many years are gingivectomy and gingivoplasty.89, 105, 410 Both have been shown to be effective for 
reducing probing depths and contouring enlarged gingival tissues. However, these surgical techniques 
are limited to areas where only soft-tissue contours need to be addressed. They are not indicated when 
access to or modification of underlying bone contours is necessary. 
As a result of the limitations of gingivectomy, use of mucogingival flaps became favored, and is more 
conducive to gaining access, pocket reduction and elimination of osseous defects. Resective 
mucogingival flaps described in the literature include apically positioned flaps with and without osseous 
re-contouring.119, 183, 288, 345 Studies have demonstrated that the effects of apically positioned flaps with 
and without osseous resection are predictable in terms of pocket reduction and long-term stability. In a 
systematic review of randomized controlled trials comparing surgical to non-surgical therapy, it was 
observed that surgical therapy consistently provided greater pocket depth reduction and clinical 
attachment gain at deeper sites (≥6 mm pocket depth) compared to non-surgical therapy.154 
Even back in the 1950s, it was a concern that deeper pockets might leave a nidus for re-infection. This 
was corroborated by more recent findings that periodontal pathogens such as P. gingivalis and 
spirochetes are more prevalent in deeper pockets,198, 272 and subjects with a higher prevalence of deeper 
pockets have a tendency to show greater disease progression over time.76, 258 Compared with non-
surgical therapy, osseous resective and modified Widman surgical procedures result in a reduction of 
probing depths and clinical attachment gains for periods from one to 12 years.48, 187, 354 
When periodontal resective procedures are utilized in the treatment of Class II and III furcations, long-
term success is uncertain. Treatment of furcated teeth is challenging. As a result, they are likely to lose 
more attachment than non-furcated teeth. Surgical techniques that have demonstrated long-term 
success in treatment of furcated teeth include root resection,143, 332 tooth hemisection and 
tunneling;143, 156 however, root caries is a frequently seen reason for failure. With the increased use of 
dental implants, these types of resective therapies are performed much less often. 
Regenerative procedures 
Regeneration, not repair, is the optimal treatment outcome for patients with significant bone and 
clinical attachment loss. However, obtaining predictable regeneration is challenging. An early surgical 
modality that resulted in periodontal regeneration was the use of bone grafts343 for treating periodontal 
infra-bony defects. Over the years, numerous grafting materials have been reported to have potential 
for true regeneration, including autogenous intra-oral and extra-oral grafts333, 344 and allografts 
(Fig. 7).159, 353 This property is due to their osteogenic, osteoinductive and osteoconductive properties. 
However, alloplastic grafting materials such as tricalcium phosphate,55, 371 porous194-196 and non-
porous425-427 hydroxyapatite, xenografts and composites have been shown to have limited regenerative 
potential, and act mainly as a filler.9 
Guided tissue regeneration and biological agents 
The concept of selectively isolating the epithelium and gingival connective tissues by use of resorbable 
and non-resorbable barrier membranes56, 131, 132, 244, 312, 313, 372, 373 to allow re-population of cells from the 
periodontal ligament, cementum and bone259 has led to clinical techniques described as guided tissue 
regeneration. The literature suggests that when treating two- or three-wall osseous defects, as well as 
Class II furcations, clinical results are achieved using guided tissue regeneration that are more 
predictable and durable than simple access flap surgery.260 Systematic reviews have confirmed the 
clinical benefits observed for bone grafting and/or guided tissue regeneration in both intra-bony defects 
and buccal Class II furcation involvements.277, 328 In addition, specific flap designs such as the modified 
papilla preservation technique85 and the simplified papilla preservation technique in areas with narrow 
inter-dental papillae have improved regenerative results due to better flap adaptation, tension-free 
closure and wound stability post-surgically.86, 394 For technically demanding multi-tooth recession 
defects, use of a coronally positioned flap via a tunneling procedure is widespread.21 As for any surgical 
approach, intensive post-operative care influences the outcomes of these regenerative procedures. 
Recent advances in understanding of the wound healing effects of growth factors and biological 
mediators,311 such as platelet-derived growth factor-BB, insulin-like growth factor,123, 241, 242, 341 enamel 
matrix derivative (e.g., Emdogain®),153, 350 and bone morphogenetic proteins on the periodontal tissues 
have given promise to the possibility of obtaining enhanced and predictable periodontal regeneration.415 
Studies utilizing growth factors and biological mediators have demonstrated significant improvement in 
clinical attachment and periodontal regeneration.68, 112, 279 
For confined (three-wall) intra-bony defects, there is robust evidence for the use of enamel matrix 
derivative in promoting tissue regeneration.400 From animal studies, it appears that there is little benefit 
of addition of bone grafting materials to enamel matrix derivative or use of a guided tissue regeneration 
membrane in such three-wall defects and class II furcation defects. However, as the number of bony 
walls decreases, there is evidence of superior regeneration when a combination of membrane and graft 
material is used to surgically repair the defect.351 Much more research must be performed to assess the 
range of materials available and their most efficient and cost–effective application in various defect 
architectures. 
A systematic review of studies on root conditioning during surgical exposure suggested that such 
treatment does not result in any significant improvement in periodontal regeneration, and provides 
little clinical advantage other than removal of a smear layer.252 
Mucogingival procedures 
A significant current focus is on improving oral–facial esthetics, creating an emphasis on mucogingival 
surgery to enhance the periodontal gingival complex. A more appropriate and contemporary term for 
such surgery is periodontal plastic surgery. Periodontal plastic surgery is designed to correct the 
dimensions and amount of gingival tissue in the esthetic zone, provide root coverage lost due to soft-
tissue recession, preserve the bone height of an extraction socket, and perform ridge augmentation. A 
detailed history of these procedures is beyond the scope of this review, and readers are referred to a 
review on the development of periodontal plastic surgery.269 
Supportive phase of treatment 
Following completion of active periodontal therapy, it is essential that a periodontal maintenance 
schedule be established. Studies have shown that tooth loss in periodontal patients is related to the 
frequency and quality of their maintenance care.38, 420 In addition, periodontal surgical therapy may fail 
in patients who are seen at infrequent maintenance intervals.103, 287 A recent systematic review 
confirmed that patients who are seen at regular intervals for supportive periodontal therapy experience 
less attachment loss and lose fewer teeth.122 Therefore, it is very important for each periodontal patient 
to receive comprehensive periodontal maintenance treatment at appropriate intervals after active 
periodontal therapy as outlined in Table 5 and Fig. 6. The periodontal disease status should be evaluated 
and communicated to the patient using the same multi-pronged approach to re-assessment as used 
after active treatment (Table 6). Intervals between periodontal maintenance visits should range from 2–
6 months depending on the patient’s disease phenotype and history, among other things. Shorter 
intervals decrease the likelihood of progression of the disease.81 
Concluding remarks 
Periodontal diseases are arguably among the most ancient and common infectious diseases affecting 
humans, leading to permanent destruction of the supporting structures of the dentition and ultimately 
tooth loss. It has been established that dental biofilm (“plaque”), consisting of many microbial species 
and their products, is an etiological agent of periodontal disease. It is widely accepted that 
immunological and inflammatory responses to dental plaque via host-parasite interaction are 
manifested by clinical signs and symptoms of periodontal diseases. The outcome of this interaction can 
be modulated by other components known as risk factors (modifiers), either inherent (genetic) or 
acquired (environmental) in nature, significantly affecting the initiation and progression of periodontal 
diseases of different types. While definitive genetic factors responsible for either susceptibility or 
resistance to periodontal diseases await definitive identification and verification, a small number of 
environmental factors affecting the pathogenesis of periodontal diseases have been described. They 
include, among others, smoking, diabetes, medication, and nutrition. 
Currently, periodontal diseases are classified based upon clinically observed disease traits using 
radiographs and clinical examination: gingivitis; chronic periodontitis; aggressive periodontitis; 
periodontitis as manifestation of systemic diseases; necrotizing ulcerative periodontitis; abscesses of the 
periodontium; periodontitis associated with endodontic lesions; and developmental or acquired 
deformities and conditions. Advances in genomics, molecular science, and personalized medicine may 
result in guidelines for unambiguous disease definition and diagnosis in the future (Fig. 8). Recent 
studies have implied that periodontal diseases and several systemic conditions, such as diabetes, 
cardiovascular disease, and pre-term delivery are interconnected, although concrete relationships still 
await to be ascertained. Therefore, by answering critical questions about the physiology of host-parasite 
interactions in periodontal diseases, scientists may be able to generate new information regarding the 
pathogenesis of systemic medical disorders, and vice versa. 
 Figure 8. Example of a case of periodontal disease that is not captured by the current classification 
system. (Top) Intra‐oral photographs of a 52‐year‐old Caucasian male who presented with a low plaque 
index (10%), low full‐mouth bleeding on probing index (<5%), and a lifelong history of hard‐bristle 
toothbrush use. There was no history of scaling and root planing or surgical debridement, and only 
recent free soft‐tissue grafts on teeth 22 and 27 for recession coverage. The overly aggressive hygiene 
probably accounted for some recession and abrasion. (Bottom) Significant generalized horizontal bone 
loss is seen in the radiographs. Its etiology is unknown. This may represent a non‐inflammatory 
destructive periodontal disease phenotype300 modified by traumatic toothbrush abrasion. 
The therapeutic efforts for controlling periodontal diseases focus on the removal of dental biofilm from 
the affected lesion, as active treatment centers on non-surgical mechanical debridement with 
antimicrobial and sometimes anti-inflammatory adjuncts. The surgical therapy aims at gaining access to 
the lesion and correcting unfavorable gingival/osseous contours to achieve a periodontal architecture 
that will provide for more efficient oral hygiene and periodontal maintenance. In addition, recent 
advances in tissue engineering have provided an efficient means to regenerate/repair periodontal 
defects, based upon principles of guided tissue regeneration and utilization of growth factors/biologic 
mediators. To maintain periodontal stability, these therapies must be supplemented by a long-term 
maintenance program (supportive periodontal therapy). 
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